Annual Report

Overview

The report describes a challenging 2022/2023, with net sales of tDKK 1.067 and an order pipeline of mDKK 14.5. It highlights nine internationally launched treatments, clinical-trial activity, MDR progress, and expansion into markets including India, Israel, and the United States. The sustainability section reports implemented diversity and inclusion efforts but places carbon measurement, environmental initiatives, and ESG targets largely in future plans for 2024.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022-2023
Period: 1 October 2022 – 30 September 2023
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services